Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B
Completed
Novartis
Phase 4
2008-03-01
This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.
A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)
Completed
Novartis Pharmaceuticals
Phase 4
2008-02-01
This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an
option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve
HBV DNA non-detectability.
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
Withdrawn
Novartis
Phase 4
1969-12-31
This study examines the effect of telbivudine compared to lamivudine on the early viral
kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral
load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
Withdrawn
University of Ulm
Phase 4
1969-12-31
This study examines the effect of telbivudine compared to lamivudine on the early viral
kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral
load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
